• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Artivion Inc.

    3/11/25 4:48:45 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care
    Get the next $AORT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001540065
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ARTIVION, INC.
    SEC File Number
    001-13165
    Address of Issuer
    1655 ROBERTS BLVD NW
    KENNESAW
    GEORGIA
    30144
    Phone
    (770) 419-3355
    Name of Person for Whose Account the Securities are To Be Sold
    JEAN F HOLLOWAY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    18020425509.864204788803/11/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/11/2025Stock Option ExerciseISSUERCheckbox not checked1802003/11/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JEAN F HOLLOWAY
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common03/06/2025212452685.29
    JEAN F HOLLOWAY
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common03/05/202547211708.57
    JEAN F HOLLOWAY
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common02/24/20255335145677.12

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/11/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/30/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jean Frames Holloway

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AORT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AORT

    DatePrice TargetRatingAnalyst
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    Financials

    Live finance-specific insights

    See more
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP constant currency basisAchieved revenue of $388.5 million for the full year of 2024 versus $354.0 million for the full year of 2023, an increase of 10% on a GAAP basis and 9% on a non-GAAP constant currency basisNet loss was $(16.5) million, or $(0.39) per fully diluted share and non-GAAP net income was $0.2 million, or $0.00 per fully diluted share in the fourth quarter of 2024. For the full year, net loss was $(13.4) million, compared to a net loss of $(30.7) million in the 2023 fiscal yearAdju

      2/24/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports Third Quarter 2024 Financial Results

      Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basisNet loss was ($2.3) million or ($0.05) per fully diluted share and non-GAAP net income was $5.0 million or $0.12 per fully diluted share in the third quarter of 2024Adjusted EBITDA increased 28% to $17.7 million in the third quarter of 2024 compared to $13.9 million in the third quarter of 2023Submitted first module of the pre-market approval application (PMA) for AMDS Hybrid Prosthesis with the U.S. Food and Drug AdministrationEnrollment completed in NEXUS TRIOMPHE clinical

      11/7/24 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Artivion with a new price target

      JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

      10/23/24 6:17:27 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street reiterated coverage on Artivion with a new price target

      Lake Street reiterated coverage of Artivion with a rating of Buy and set a new price target of $28.00 from $32.00 previously

      9/27/22 11:06:42 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Artivion with a new price target

      Lake Street initiated coverage of Artivion with a rating of Buy and set a new price target of $32.00

      8/8/22 9:08:33 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 23, 2023 - FDA Roundup: May 23, 2023

      For Immediate Release: May 23, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA and the Veterans Health Administration announced a new collaboration to jointly develop emergency preparedness and response tools and protocols intended to help increase medical product manufacturing capacity and flexibility, and improve resilie

      5/23/23 4:06:19 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Clinical & MD Affair Stanton Marshall S. sold $307,265 worth of shares (10,548 units at $29.13), decreasing direct ownership by 9% to 105,332 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      5/12/25 2:31:31 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, General Counsel Holloway Jean F exercised 19,092 shares at a strike of $21.55 and sold $425,510 worth of shares (18,020 units at $23.61), increasing direct ownership by 0.55% to 197,184 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:41:12 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Davis John E exercised 15,910 shares at a strike of $21.55 and sold $356,549 worth of shares (15,100 units at $23.61), increasing direct ownership by 0.39% to 208,778 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/12/25 3:32:23 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Artivion Inc.

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      11/8/24 10:29:29 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Artivion Inc.

      SC 13G - ARTIVION, INC. (0000784199) (Subject)

      3/11/24 5:45:25 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Artivion Inc. (Amendment)

      SC 13G/A - ARTIVION, INC. (0000784199) (Subject)

      2/14/24 6:18:56 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/5/25 4:01:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

      ATLANTA, May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on May 15, 20

      5/14/25 4:01:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Reports First Quarter 2025 Financial Results

      First Quarter Highlights: Achieved revenue of $99.0 million in the first quarter of 2025 versus $97.4 million in the first quarter of 2024, an increase of 2% on a GAAP basis and 4% on a non-GAAP constant currency basisNet loss was $(0.5) million, or $(0.01) per fully diluted share and non-GAAP net income was $2.5 million, or $0.06 per fully diluted share in the first quarter of 2025Adjusted EBITDA increased 1% to $17.5 million in the first quarter of 2025 compared to $17.3 million in the first quarter of 202430-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a 63% reduction in the major adverse event (MAE) rate compared with reference perf

      5/5/25 4:05:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting

      30-Day Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate 63% Reduction in Major Adverse Event (MAE) Rate compared with Reference Performance Goal ATLANTA, May 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle, Washington. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with NEXUS.  Patients enrolled were at high risk for open surgical repair

      5/5/25 7:00:00 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Leadership Updates

    Live Leadership Updates

    See more
    • Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

      Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA, Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance A. Berry as the Company's Chief Financial Officer, effective as of December 4, 2023. In this role, Mr. Berry joins Artivion's executive leadership team and replaces Mr. D. Ashley Lee, who will retire at the end of the year after a successful and long tenure with the Company and a distinguished career in the medical device industry. Artivion also reaffirmed its full-year 2023 financial guidance that was provided on November 2, 2023.

      12/6/23 4:15:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Sequana Medical announces results of Special General Meeting of Shareholders

      PRESS RELEASEREGULATED INFORMATION26 June 2023, 06:00 pm CEST Dr. Kenneth Macleod appointed as non-executive director Ghent, Belgium – 26 June 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Special General Meeting of Shareholders were approved at the meeting held today at 09:00 am CEST. The items on the agenda of the meeting included the appointment of Dr. Kenneth Macleod as non-executive director of the Company and the approval in accordance with Article 7:151 of the Belgian Companies and Asso

      6/26/23 12:00:00 PM ET
      $AORT
      $PHAR
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Elizabeth Hoff Joins Artivion Board of Directors

      ATLANTA, Sept. 29, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Elizabeth A. Hoff to its Board of Directors effective October 1, 2022. "We are excited to welcome Elizabeth to our Board of Directors," said Pat Mackin, Chairman, President, and Chief Executive Officer. "Elizabeth brings a wealth of knowledge in the medical device industry demonstrated by her tenure in the aortic space leading teams focused on the development and commercial launch of innovative healthca

      9/29/22 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    SEC Filings

    See more
    • Artivion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      5/16/25 2:32:34 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      5/14/25 4:05:55 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Artivion Inc.

      SCHEDULE 13G - ARTIVION, INC. (0000784199) (Subject)

      5/12/25 10:24:40 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care